Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Analysts at Leerink Swann decreased their FY2017 EPS estimates for Intercept Pharmaceuticals in a research note issued on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings per share of ($13.17) for the year, down from their prior forecast of ($13.14). Leerink Swann has a “Hold” rating and a $60.00 price objective on the stock.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.04). The business had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. Intercept Pharmaceuticals’s revenue was up 173.1% compared to the same quarter last year. During the same period last year, the business earned ($4.84) EPS.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at $56.02 on Thursday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. The stock has a market capitalization of $1,340.70, a price-to-earnings ratio of -3.79 and a beta of -2.13. Intercept Pharmaceuticals has a one year low of $51.05 and a one year high of $135.59.
A number of large investors have recently added to or reduced their stakes in the stock. WFG Advisors LP boosted its holdings in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the period. Voya Investment Management LLC boosted its holdings in Intercept Pharmaceuticals by 4.7% in the second quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock valued at $847,000 after purchasing an additional 313 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Intercept Pharmaceuticals by 23.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 470 shares during the period. Alliancebernstein L.P. boosted its holdings in Intercept Pharmaceuticals by 6.2% in the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock valued at $1,145,000 after purchasing an additional 550 shares during the period. Finally, California Public Employees Retirement System boosted its holdings in Intercept Pharmaceuticals by 2.3% in the second quarter. California Public Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $3,753,000 after purchasing an additional 700 shares during the period. Hedge funds and other institutional investors own 75.48% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/15/intercept-pharmaceuticals-inc-icpt-forecasted-to-earn-fy2017-earnings-of-13-17-per-share.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.